Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Anti-TNF-alpha antibody reduces pain-behavioral changes induced by epidural application of nucleus pulposus in a rat model depending on the timing of administration.

Authors: Sasaki, N  Kikuchi, S  Konno, S  Sekiguchi, M  Watanabe, K 
Citation: Sasaki N, etal., Spine (Phila Pa 1976). 2007 Feb 15;32(4):413-6.
Pubmed: (View Article at PubMed) PMID:17304130
DOI: Full-text: DOI:10.1097/01.brs.0000255097.18246.bc

STUDY DESIGN: An experimental animal study. OBJECTIVE: To study if antitumor necrosis factor-alpha (TNF-alpha) antibody, which is administered at different times, reduces the pain behavior induced by application of nucleus pulposus (NP) to the nerve root. SUMMARY OF BACKGROUND DATA: Treatment with TNF-alpha inhibitor reduces the pain-related behavior induced by epidural application of NP in rats. METHODS: Left L5 partial laminectomy was performed and NP was applied to the L5 nerve root in 24 rats. The rats were divided into 4 groups. In 3 groups, anti-rat TNF-alpha antibody was intravenously administered immediately after, or 6 or 20 days after NP application. The fourth group was not treated with anti-rat TNF-alpha antibody (untreated rats). The withdrawal threshold of the plantar surface was determined 1 day before up through 28 days after NP application. RESULTS: The withdrawal threshold of rats that had been treated with anti-rat TNF-alpha antibody immediately after or 6 days after, but not 20 days after, NP application, was significantly higher than that of the untreated rats. CONCLUSIONS: Anti-TNF-alpha antibody reduced allodynia only when it was administered soon after the onset of allodynia. Late administration of anti-TNF-alpha antibody did not have an antiallodynic effect.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 7394757
Created: 2013-11-04
Species: All species
Last Modified: 2013-11-04
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.